A phase 1/2 study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ

被引：0
|
作者：
Bryce, Richard
Tosone, Christine
Sullivan, James C.
Linback, Tammy
Steinberg, Gary D.
机构：
[1] EnGene Inc, Boston, MA USA
[2] RUSH Univ, Med Coll, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4626
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Re: Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials
    不详
    JOURNAL OF UROLOGY, 2021, 206 (04): : 1061 - 1062
  • [22] A multicenter clinical trial of intravesical BCG in combination with ALT-803 in patients with BCG-unresponsive non-muscle invasive bladder cancer.
    Chamie, Karim
    Salmasi, Amirali
    Rosser, Charles Joel
    Rock, Amy
    Ferguson, Lydia
    Wong, Hing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [23] EG-70 (detalimogene voraplasmid), a novel, investigational non-viral immunotherapy for non-muscle-invasive bladder cancer: mechanism of action and translation to the clinic
    Sullivan, J.
    Goulet, M. L.
    Dauphinee, S.
    Veilleux, D.
    Louis, K.
    Lazure, D.
    Stevenson, S.
    Bilimoria, D.
    Zamzameer, F.
    Chen, X.
    Sublemontier, S.
    Amirkhani, S.
    Fleet, C.
    Bryce, R.
    Cheung, A.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S169 - S170
  • [24] Hyperthermic intravesical chemotherapy for BCG unresponsive or BCG ineligible non-muscle invasive bladder cancer
    de Jong, Joep J.
    Rosier, Marloes
    Boormans, Joost L.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (10) : 613 - 613
  • [25] Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
    Narayan, V.
    Boorjian, S.
    Alemozaffer, M.
    Konety, B. R.
    Gomella, L.
    Kamat, A. M.
    Lerner, S. P.
    Svatek, R. S.
    Karsh, L.
    Canter, D.
    Lotan, Y.
    Inman, B. A.
    Yang, M.
    Garcia-Horton, V.
    Sawutz, D.
    Parker, N.
    Dinney, C. P. N.
    EUROPEAN UROLOGY, 2021, 79 : S1026 - S1027
  • [26] US CLINICAL PRACTICE PATTERNS OF INTRAVESICAL CHEMOTHERAPY FOR BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER AMONG CARCINOMA IN SITU AND PAPILLARY-ONLY TUMORS
    Abou, Chakra Mohamad
    Michael, O'Donnell A.
    Neal, Shore D.
    Rachelle, Dillon
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S54 - S55
  • [27] PHASE 3 STUDY OF VICINEUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: 24-MONTH RESULTS
    O'Donnell, Michael
    Shore, Neal
    Keane, Thomas
    Jewett, Michael
    Dickstein, Rian
    Wolk, Fred
    Dillon, Rachelle L.
    Cizeau, Jeannick
    Kassouf, Wassim
    JOURNAL OF UROLOGY, 2021, 206 : E296 - E297
  • [28] S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer
    Singh, Parminder
    Catherine, Tangen
    Lerner, Seth P.
    McConkey, David
    Plets, Melissa
    Lucia, M. Scott
    Woods, Michael
    Bivalacqua, Trinity
    Kassouf, Wassim
    Bangs, Richard Carlton
    Thompson, Ian Murchie
    Black, Peter C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
    Marquette, T.
    Walz, J.
    Rybikowski, S.
    Maubon, T.
    Branger, N.
    Fakhfakh, S.
    Verde, K. L.
    Dermeche, S.
    Gravis, G.
    Pignot, G.
    PROGRES EN UROLOGIE, 2020, 30 (01): : 35 - 40
  • [30] PATIENT PREFERENCES FOR TREATMENT OF BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: A DISCRETE CHOICE EXPERIMENT
    Collacott, H.
    Rentz, A.
    Krucien, N.
    Heidenreich, S.
    Ghatnekar, O.
    VALUE IN HEALTH, 2022, 25 (07) : S298 - S299
12345